In a large Chinese study, in certain RCC subgroups cancer-specific survival outcomes were better with partial rather than radical nephrectomy.
A meta-analysis was unable to find a conclusive relationship between physical activity and the risk of prostate cancer, though a reduced risk was suggested.
A large phase I trial offers further evidence that the anti–PD-L1 agent avelumab is generally well tolerated and results in relatively few serious adverse events.
Incorporating MRI-based parameters into a risk model could cut down on the number of unnecessary biopsies performed in patients with suspected prostate cancer.
The observed narrowing of racial disparities in prostate cancer outcome since the advent of PSA screening is not as large as previously believed.
The approval of the oral androgen-receptor inhibitor apalutamide (Erleada) is the first to be based on metastasis-free survival.
Adjuvant platinum-based chemotherapy is associated with delayed metastasis among patients diagnosed with upper-tract urothelial carcinoma, according to findings from the phase III POUT trial.
Pazopanib was not associated with prolonged progression-free survival compared with temsirolimus among patients with advanced clear-cell renal cell carcinoma, but a subgroup analysis of intermediate-risk patients offered some reason for optimism.
Long-term follow-up showed that atezolizumab remained well tolerated over more than 3 years, with durable clinical benefit in metastatic urothelial carcinoma.
Adjuvant therapy with sunitinib after nephrectomy was associated with increased mortality among older women with renal cell carcinoma, according to a subgroup analysis of data from the ASSURE trial.